Sign in
Trending NewsTrending News

Covid-19 vaccine trial likely to conclude by Nov, production may start in early 2021: AstraZeneca

The countries will make 150 million to 250 million initial doses of the potential Covid-19 vaccine designed by scientists at the University of Oxford after the required trials, Argentine president Alberto Fernandez and Mexican foreign minister Marcelo Ebrard said in messages on Twitter

Updated on: Aug 13, 2020, 20:31:31 IST
As Prefered on
Share via
  • facebook
  • twitter
  • linkedin
Copy link
  • copy link

Mexico and Argentina have reached agreements to produce the UK drugmaker AstraZeneca Plc’s promising Covid-19 vaccine for Latin America, the nations’ governments said.

Phase III trials of Covid-19 vaccine were expected to conclude by November or December, AstraZeneca said. (Reuters File Photo)
Phase III trials of Covid-19 vaccine were expected to conclude by November or December, AstraZeneca said. (Reuters File Photo)

The countries will make 150 million to 250 million initial doses of the potential Covid-19 vaccine designed by scientists at the University of Oxford after the required trials, Argentine president Alberto Fernandez and Mexican foreign minister Marcelo Ebrard said in messages on Twitter on Wednesday night. Billionaire Carlos Slim’s foundation is helping finance the plan, Ebrard said.

Follow latest updates on coronavirus here

The goal is to produce the vaccine as of the first half of next year, and there will be no profits from it during the pandemic, Fernandez said in his statement following a meeting with representatives of AstraZeneca. His health minister said Argentina will prioritize getting the vaccine to the elderly, medical professionals and people with pre-existing conditions.

The vaccine’s phase 3 results are due as early as November, and Mexicans will have universal access to the vaccine, which will be free, Ebrard said at President Andres Manuel Lopez Obrador’s news conference on Thursday morning. Lopez Obrador said the cost to Mexico will be less than 25 billion pesos, ($1.12 bilion).

“This is a deal for production in Mexico of the vaccine that today is considered the most advanced in the world,” Ebrard said. Manufacturing is scheduled for the first quarter of 2021, according to AstraZeneca’s Mexico country chief, Sylvia Varela.

Mexico is third in the world in confirmed Covid-19 deaths with more than 53,000, trailing only Brazil and the US, and Latin America accounts for half of the 10 countries with the most cases globally.

Click here for complete coronavirus coverage

Slim’s son, America Movil chairman Carlos Slim Domit, also joining the news conference, said that the collaboration will allow Mexico to obtain the vaccine one year early. Biotechnology company mAbxience will produce the active substance in Argentina and Mexican laboratory Liomont will complete the process of formulation, Fernandez said Wednesday. The finished vaccine will then be exported to the rest of Latin America.

ABOUT THE AUTHOR

Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.